Document is current
Any future updates will be listed below
-
Authors
Mackall, Crystal L. https://orcid.org/0000-0001-6323-4304
Bollard, Catherine M. https://orcid.org/0000-0001-5140-9090
Goodman, Nancy
Carr, Casey
Gardner, Rebecca
Rouce, Rayne
Sotillo, Elena https://orcid.org/0000-0002-3993-1932
Stoner, Rich
Urnov, Fyodor D.
Wayne, Alan S.
Park, Julie
Kohn, Donald B. https://orcid.org/0000-0003-1840-6087
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 30 April 2024
First Online: 17 June 2024
Competing interests
: C.L.M. holds multiple patents in the arena of CAR T cell therapeutics; receives royalties from CARGO through the US National Institutes of Health and Stanford; holds equity in CARGO Therapeutics, Link Cell Therapies, Ensoma and GBM NewCo, which are developing CAR-based therapies; consults for CARGO, Link, Immatics, Ensoma and GBM NewCo; and receives research funding from Lyell Immunopharma and Tune Therapeutics. C.M.B. has filed patents in the arena of cell therapies, including CAR-modified cell therapies; is a scientific cofounder of Mana Therapeutics and Catamaran Bio; is on the Board of Directors of Cabaletta Bio; and holds stock in Repertoire Immune Medicine and Neximmune, all of which are developing cell therapies (including CAR-based therapies) for cancer or immune-mediated disorders. In addition, C.M.B. serves on the drug safety monitoring board for SOBI and on the scientific advisory board of Minovia TX. C.M.B has also served as president of FACT since 2021. N.G. is a cofounder and holds equity in CARGO Therapeutics. R.A.G. has patents related to CAR therapy and receives royalty payments related to patents from Juno Therapeutics. R.H.R. has received consulting fees from Pfizer and honoraria from Novartis. R.M.S. holds multiple patents in the area of CRISPR bioinformatics and biomanufacturing technologies; is the founder of Exthymic, a cell manufacturing instrument company; sits on the board of Indee Labs; and holds equity in Exthymic, Resilience (a Contract Development and Manufacturing Organization) and Synthego (RNA reagent manufacturer). F.D.U. is a scientific cofounder of Tune Therapeutics; holds equity in, and is a compensated advisor to, Tune Therapeutics and Cimeio Therapeutics; is a paid advisor to Ionis Pharmaceuticals; is a paid consultant to Vertex Pharmaceuticals on the exa-cel program; and receives salary support from the Danaher Corporation. A.S.W. receives institutional research funding (Children’s Hospital Los Angeles) from Kite, A Gilead Company. In addition, A.S.W. has served on advisory boards for Wugen, Kite and Institut de Recherches Internationales Servier, all for cell therapy product development. D.B.K. is an inventor for the University of California Regents for a lentiviral vector to treat ADA-SCID.
